Results 161 to 170 of about 88,904 (264)

No Effect of Low‐Dose Aspirin Versus Placebo as Add‐On Treatment in Bipolar Disorder—Results From a Randomised Controlled Trial (the A‐Bipolar RCT)

open access: yesActa Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Robust evidence associates immunoinflammatory dysfunction and bipolar disorder (BD), with immune dysregulation present in patients newly diagnosed with BD. This suggests that anti‐inflammatory agents, like low‐dose aspirin (LDA), might be repurposed in the treatment of early‐stage BD.
Caroline Fussing Bruun   +9 more
wiley   +1 more source

In Vitro Hemocompatibility of the BiVACOR Total Artificial Heart in Continuous and Pulsatile Flow

open access: yesArtificial Organs, EarlyView.
BiVACOR's total artificial heart generates remarkably similar hemocompatibility when operated with a pulse or during continuous flow. Under both conditions, hemolysis and von Willebrand Factor multimers were similar to a commercial reference device after 6 h in vitro evaluation.
Antony P. McNamee   +6 more
wiley   +1 more source

Rare Etiologies of Upper Gastrointestinal Bleeding: A Narrative Review. [PDF]

open access: yesJ Clin Med
Dina I   +4 more
europepmc   +1 more source

Hemocompatibility Outcomes After Aspirin Withdrawal in Long‐Term HeartMate 3 Left Ventricular Assist Device Patients on Vitamin K Antagonists

open access: yesArtificial Organs, EarlyView.
Aspirin discontinuation in long‐term, stable Heart Mate 3 LVAD patients maintained on Vitamin K antagonists did not increase hemocompatibility‐related adverse events. These findings support the safety of simplified antithrombotic therapy and extend randomized evidence for aspirin avoidance to the long‐term management of Heart Mate 3 recipients ...
Melanie Arnreiter   +8 more
wiley   +1 more source

Complex upper gastrointestinal bleeding: A case of combined peptic ulcer disease and ruptured gastroduodenal artery aneurysm in a pediatric patient

open access: gold
Phuong Lien Tran   +7 more
openalex   +1 more source

Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
In a multi‐centre study of obeticholic acid in primary biliary cholangitis, 45% discontinued the drug over 4 years, with 11% moving to combination therapy (fibrates). Of those continuing, response rates increased from 37% (1 year) to 55% (4 years). Non‐response at 12 months and cirrhosis were independent predictors of liver‐related events.
Nadir Abbas   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy